RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Colon Channel

subscribe to Colon newsletter
Latest Research : Cancer : Colon

   EMAIL   |   PRINT
Chemotherapy options improve for patients with advanced colorectal cancer

Jun 7, 2005 - 11:59:00 AM
"This study for the first time shows that an oral based Cap/Ox regimen is able to substitute for the complex intravenous 5-FU 2-drug- or 3-drug-combination in colorectal cancer. Large trials are underway to definitely answer this question with several thousand patients; however, the results of these studies will not be available before 2006,"

 
[RxPG] For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC). The findings are reported today at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

"We conducted this phase III study because the combination of oral capecitabine and oxaliplatin showed promising effects in different phase II studies. The idea of this study was to look whether CAPOX can replace the standard treatment of iv. 5-FU/folinic acid in patients with MCRC", said lead author Dr. Hendrik-Tobias Arkenau, from Clinic Bremen East in Germany.

From 2002 to 2004, the authors randomly assigned 476 patients who had not undergone previous chemotherapy to receive either FUFOX (5-fluorouracil (5-FU) 2000mg/m² 24h infusion, folinic acid 500mg/m², oxaliplatin 50mg/m² d1,8,15,22; q5 wks) or CAPOX (capecitabine 1000mg/m² bid d1-14, oxaliplatin 70mg/m² d1 and 8; q3 wks).

So far, based on an analysis of 2541 treatment cycles (1026 FUFOX, 1515 CAPOX), both regimens are comparably toxic and showed similar response rates (ITT-RR: 50% FUFOX and 47% CAPOX, p=NS).

Median length of time without progression of disease was 34.7 weeks in the FUFOX arm and 30.3 weeks in the CAPOX arm, respectively, a difference that was not statistically different (p=0.1), the authors found. Additionally, both treatment arms showed similar overall survival, FUFOX 74.9 weeks and CAPOX 70.9 weeks, p=0.72.

The authors conclude that CAPOX shows comparable efficacy and toxicity profiles compared to the FUFOX regimen in patients chemonaive MCRC.

"This study is important for patients because the CAPOX regimen is more convenient to administer. Patients will appreciate needing to come only twice in three weeks as outpatients to receive the 2 hourly oxaliplatin dose. Especially in the palliative setting of MCRC, patients gain more autonomy and improved quality of life," Dr. Arkenau said.

"We hope that oral capecitabine plus oxaliplatin will become the new standard treatment in first-line treatment for patients with metastatic colorectal carcinoma."

Commenting on the study, Professor Hans Joachim Schmoll of Martin-Luther-Universität Halle-Wittenberg in Germany said the results of the trial "are of major importance for the clinical routine, at least for those patients who would like to avoid intravenous infusional protocols, ports and pumps."

The 5-FU-infusion in combination with cytostatic agents like oxaliplatin or irinotecan in patients with colorectal cancer is complicated and needs support and a pump for the patient, he said. This is a cause of major discomfort, meaning it is important to investigate alternatives substituting the infusion of 5-FU by oral agents.

"This study for the first time shows that an oral based Cap/Ox regimen is able to substitute for the complex intravenous 5-FU 2-drug- or 3-drug-combination in colorectal cancer. Large trials are underway to definitely answer this question with several thousand patients; however, the results of these studies will not be available before 2006," Professor Schmoll said.



Publication: European Society for Medical Oncology
On the web: http://www.esmo.org/ 

Advertise in this space for $10 per month. Contact us today.


Related Colon News
Screening for colon cancer depends on location, race and ethnicity
Alcohol, cigarettes can cause bowel cancer
TSPAN1 expression-a useful tool to evaluate prognosis in colorectal cancer
Advances in screening and markers improve early detection of colorectal cancer
Rice bran can reduce the risk of intestinal cancer
Simutaneous removal of primary and liver metastasis favourable in some colorectal cancer patients
Follow-up endoscopic surveillance in colorectal cancer patients improves survival
Researchers identify cell pathway which plays a critical role in the development of colon cancer
Regular aerobics protects men from colon cancer
Role for MicroRNAs in Oxygenation, Nourishing of Colon Tumors

Subscribe to Colon Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)